Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00309855 | Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men | PHASE1 | COMPLETED | 80 | — | — | Dec 1, 2005 | Aug 1, 2008 | Jul 31, 2012 | 1 | United States |
GH will be measured 4 different times mornings within 16-21 days following the first testosterone injection (day 1).
| Arm | Type | Description |
|---|---|---|
| Double Placebo | PLACEBO_COMPARATOR | (i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days) |
| Testosterone IM and oral placebo | OTHER | IM injections weekly x three injections and oral placebo once daily x 21 days |
| Testosterone and Oral Anastrozole | OTHER | IM injections weekly x 3 injections and oral daily x 21 days |
| Testosterone and Dutasteride | OTHER | IM injections weekly x 3 injections and oral once daily x 21 days |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | im and orally |
| Testosterone | DRUG | injections |
| Anastrazole | DRUG | orally x 21 days |
| Dutasteride | DRUG | orally x 21 days |
Inclusion Criteria: * healthy men between the ages of 50 and 80; * normal weight (within 30% of ideal body weight defined by New York Metropolitan Life tables); and * normal hematocrit (greater than 38%); * community dwelling; and * voluntarily consenting Exclusion Criteria: * recent use of psych...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 1 | NA | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | NA | Rosuvastatin |
| Ultragenyx Pharmaceutical, Inc. | RARE | 1 | — | Undisclosed |